Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR–MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion–Driven NSCLC
Open accessThe DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Abstract
EGFR exon 20 insertion driver mutations (Exon20ins) in non–small cell lung cancer (NSCLC) are insensitive to EGFR tyrosine kinase inhibitors (TKI). Amivantamab (JNJ-61186372), a bispecific antibody targeting EGFR–MET, has shown preclinical activity in TKI-sensitive EGFR-mutated NSCLC models and in an ongoing first-in-human study in patients with advanced NSCLC. However, the activity of amivantamab in Exon20ins-driven tumors has not yet been described. Ba/F3 cells and patient-derived cells/organoids/xenograft models harboring diverse Exon20ins were used to characterize the antitumor mechanism of amivantamab. Amivantamab inhibited proliferation by effectively downmodulating EGFR–MET levels and inducing immune-directed antitumor activity with increased IFNγ secretion in various models. Importantly, in vivo efficacy of amivantamab was superior to cetuximab or poziotinib, an experimental Exon20ins-targeted TKI. Amivantamab produced robust tumor responses in two Exon20ins patients, highlighting the important translational nature of this preclinical work. These findings provide mechanistic insight into the activity of amivantamab and support its continued clinical development in Exon20ins patients, an area of high unmet medical need. Significance: Currently, there are no approved targeted therapies for EGFR Exon20ins–driven NSCLC. Preclinical data shown here, together with promising clinical activity in an ongoing phase I study, strongly support further clinical investigation of amivantamab in EGFR Exon20ins–driven NSCLC. This article is highlighted in the In This Issue feature, p. 1079
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“These results were replicated in clinical trials (for example, NCT04538664), eventually leading to the approval of amivantamab by the EMA for the treatment of non-small cell lung cancer.”
From Human disease models in drug development (2023) · cites this paper as [115]
In the citing paper
“the efficacy of amivantamab, a bispecific antibody against EGFR and the mesenchymal–epithelial transition receptor, was preclinically tested in patient-derived cells and organoids that harbour EGFR Exon20ins mutations115.”
From Human disease models in drug development (2023) · cites this paper as [115]
Citations
Cites
The 2015 World Health Organization Classification of Lung Tumors
Travis, W. D., Brambilla, E., Nicholson, A. G., Yatabe, Y., Austin, J. H. M., Beasley, M. B., Chirieac, L. R., Dacic, S., Duhig, E., Flieder, D. B., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000630 · Cited by 4,520
Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs
Kris, M. G., Johnson, B. E., Berry, L. D., Kwiatkowski, D. J., Iafrate, A. J., Wistuba, I. I., Varella-Garcia, M., Franklin, W. A., Aronson, S. L., Su, P.-F., et al. (2014) · JAMA · doi:10.1001/jama.2014.3741 · Cited by 1,724 · cited 1×
“Nearly 20% of Caucasians and up to 50% of Asians with lung adenocarcinomas harbor mutations in EGFR (3,4).”
BackgroundLong‐term expanding human airway organoids for disease modeling
Sachs, N., Papaspyropoulos, A., Zomer‐van Ommen, D. D., Heo, I., Böttinger, L., Klay, D., Weeber, F., Huelsz‐Prince, G., Iakobachvili, N., Amatngalim, G. D., et al. (2019) · The EMBO Journal · doi:10.15252/embj.2018100300 · Cited by 1,082 · cited 1×
“PDO Culture PDOs (YUO-029 and YUO-036) were established as described previously (46).”
MethodGazdar, A. F. (2009) · Oncogene · doi:10.1038/onc.2009.198 · Cited by 991 · cited 1×
“tyrosine kinase inhibitors (TKIs) such as erlotinib, afatinib and osimertinib (5,6).”
BackgroundRegulation of human NK-cell cytokine and chemokine production by target cell recognition
Fauriat, C., Long, E. O., Ljunggren, H.-G., & Bryceson, Y. T. (2010) · Blood · doi:10.1182/blood-2009-08-238469 · Cited by 891 · cited 1×
“It is known that inflammatory cytokines such as IFN-γ and TNFα are secreted from infected monocytes and activated NK cells during ADCC, encouraging antigen presentation and adaptive immune responses (36,37).”
BackgroundMutant p53 as a guardian of the cancer cell
Mantovani, F., Collavin, L., & Del Sal, G. (2019) · Cell Death & Differentiation · doi:10.1038/s41418-018-0246-9 · Cited by 775 · cited 1×
“Given that mutant TP53 is associated with EGFR-TKI resistance (30) and the depleted mutant TP53 restored the sensitivity of amivantamab by downregulation of p-ERK, induction of p-ERK following amivantamab treatment in YU-1163 cells might be a key regulator of cell survival potentially through the crosstalk between mut…”
BackgroundYasuda, H., Park, E., Yun, C.-H., Sng, N. J., Lucena-Araujo, A. R., Yeo, W.-L., Huberman, M. S., Cohen, D. W., Nakayama, S., Ishioka, K., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3007205 · Cited by 571 · cited 1×
“In contrast, the EGFR exon 20 mutations encompass nucleotides that translate into amino acids at position 762-823, and include a C-helix (762–766) followed by a loop (767–775) (7).”
BackgroundNK cell-mediated antibody-dependent cellular cytotoxicity in cancer immunotherapy
Wang, W. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00368 · Cited by 567 · cited 1×
“The effector cells, mainly natural killer (NK) cells, trigger degranulation and subsequent cytokine production, resulting in the elimination of the target cells (33).”
BackgroundIntra-tumour diversification in colorectal cancer at the single-cell level
Roerink, S. F., Sasaki, N., Lee-Six, H., Young, M. D., Alexandrov, L. B., Behjati, S., Mitchell, T. J., Grossmann, S., Lightfoot, H., Egan, D. A., et al. (2018) · Nature · doi:10.1038/s41586-018-0024-3 · Cited by 551
Costa, D. B., Halmos, B., Kumar, A., Schumer, S. T., Huberman, M. S., Boggon, T. J., Tenen, D. G., & Kobayashi, S. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040315 · Cited by 499 · cited 1×
“As EGFR-TKIs have been reported to drive apoptosis in NSCSL cells harboring sensitizing EGFR mutations (24,25), we investigated whether treatment with amivantamab resulted in engagement of the apoptotic machinery.”
Background
Cited by
Items 201–300 of 301
Current paradigm of EGFR in non-small cell lung cancer: A long way forward
Miyamura, B. V., Mambetsariev, I., Fricke, J., Arias-Romero, J., Cadman, K., Shrestha, S., Pisick, E. P., Nguyen, D., Malhotra, J. D., Reyes, A., et al. (2025) · Med · doi:10.1016/j.medj.2025.100803 · Cited by 6
Watanabe, N., Horio, Y., & Fujiwara, Y. (2022) · Annals of Translational Medicine · doi:10.21037/atm-2022-56 · Cited by 6
“Amivantamab (JNJ-61186372) is a novel, fully humanized bispecific IgG1 that targets EGFR and the mesenchymal epithelial transition factor (MET) receptor (48,49).”
Chen, X., Zha, W., Su, M., Meng, N., Cao, S., Niu, B., & Qi, X. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1053805 · Cited by 5
“The other is amivantamab (JNJ-61186372), which is a bispecific antibody targeting EGFR and MET (Yun et al., 2020).”
BackgroundLiu, J., Xiang, Y., Fang, T., Zeng, L., Sun, A., Lin, Y., & Lu, K. (2023) · Clinical Lung Cancer · doi:10.1016/j.cllc.2023.11.010 · Cited by 9
Arter, Z., & Nagasaka, M. (2024) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s467169 · Cited by 7
Targeting exon 20 insertion mutations in lung cancer
Yang, Y., & Wang, Y. (2022) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000919 · Cited by 6
Not All EGFR Exon 20 Insertions Are Created Equal
Lin, Y., & Shih, J. (2020) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2020.100069 · Cited by 7
Mutukuru, M., Kandula, S. R., Ramakrishna, V., Sanka, P., Sidde, G. P., Muzzamil, S. M., Uppara, H. B., & Prasad, P. D. (2026) · International Journal of Cancer · doi:10.1002/ijc.70318 · Cited by 5
Zhao, S., Liu, X., Wang, J., Tang, B., Long, Q., Tang, X., Dai, J., Jiang, Y. M., & Liu, Q. (2026) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2026.103138 · Cited by 4
A comprehensive review of small molecule drugs approved by the FDA in 2024: Advance and prospect
Bai, Y., Duan, Q.-C., Seng, D., Xu, Y., Ren, H., Zhang, J., Shen, D., Yang, L., Liu, H., & Yuan, S. (2025) · Chinese Chemical Letters · doi:10.1016/j.cclet.2025.111025 · Cited by 5
Shi, Y., Xu, Y., & Wang, M. (2024) · BMC Cancer · doi:10.1186/s12885-024-12797-3 · Cited by 5
“OS, overall survival; PFS, progression-free survival; ORR, objective response rate; AEs, adverse events EGFR/MET, and it was the first FDA-approved agent for the second-line treatment of EGFR exon20ins-positive patients [39].”
BackgroundThomson, C., Braybrooke, E. L., Colclough, N., Davies, N. L., Floc’h, N., Greenwood, R. D. R., Guerot, C. M., Hargreaves, D., Johnström, P., Khurana, P., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01792 · Cited by 4
Maione, P., Palma, V., Pucillo, G., & Gridelli, C. (2025) · Cancers · doi:10.3390/cancers17050847 · Cited by 4
“In fact, it exerts its action by ligand blocking, receptor degradation, and immune actions by recruitment of effector cells as natural killer cells [30–32].”
Severe scalp ulcerations and granulomata during treatment with amivantamab
Zhou, J. J., Chen, L. N., Lehan, T., Herzberg, B., Henick, B. S., Pitman, M. J., Gallitano, S. M., & Shu, C. A. (2023) · Current Problems in Cancer Case Reports · doi:10.1016/j.cpccr.2023.100273 · Cited by 4
Wang, Q., Wang, W., Pan, W., Lv, X., Zhang, L., Zheng, K., Tian, F., & Xu, C. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.884798 · Cited by 4
“The development of novel targeted drugs, such as poziotinib (9), mobocertinib (TAK-788) (10), and amivantamab (JNJ-61186372) (11), have shown better efficacy in the treatment of EGFR exon 20 insertion mutations.”
BackgroundMetro, G., Giglio, A. D., Ricciuti, B., Siringo, M., Marinelli, D., Gelibter, A. J., Pecci, F., Berardi, R., Cantini, L., Federico, A. D., et al. (2022) · Drugs in Context · doi:10.7573/dic.2022-3-9 · Cited by 4
Chen, Y. C., Du, Y., Ni, J., Wang, D., Zhan, P., Song, Y., Han, H., & Lv, T. (2025) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359251405044 · Cited by 3
“64 With the modification of the agent structure to increase tumor selectivity and optimize target selection, the efficacy and safety will be further improved.”
Minchom, A., Cho, B. C., Leighl, N. B., Johnson, M. L., Sabari, J. K., Lee, S.-H., Lee, K. H., Kim, Y. J., Sanborn, R. E., O’Neil, B. H., et al. (2026) · Clinical Lung Cancer · doi:10.1016/j.cllc.2026.02.001 · Cited by 4
Self-citationPatient-derived tumor organoids for new drug development: promises and challenges
He, M., Wu, Y., Du, F., Wang, J., Zhang, H., & Han, J. (2026) · Investigational New Drugs · doi:10.1007/s10637-026-01605-3 · Cited by 3
“Additionally, they are also used to assess the in vivo efficacy and toxicity of drugs to improve the efficiency of drug development and success rates of clinical trials [17].”
TAS3351 is a brain penetrable EGFR-TKI that overcomes T790M and C797S resistant mutations
Kasuga, H., Kataoka, Y., Yamamoto, F., Miyamoto, R., Tsuji, S., Suzuki, T., & Mizuarai, S. (2026) · Communications Medicine · doi:10.1038/s43856-026-01546-1 · Cited by 3
“Amongthese,thecombinationof amivantamab,anEGFR-METbispeci fi c antibody with immune cell-directingactivity 62 ,andlazertinib,aCNS-penetrantthird-generationEGFR-TKI 63,64 , has demonstrated superior ef fi cacy compared to osimertinib as a fi rst-line treatment for EGFR-mutated advanced NSCLC 65 .”
Wang, Y., Zhang, G., Zhou, Z., Zhang, N., Jiang, H., Liu, Y., Fu, T., Zhu, Y., & Li, J. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202402884 · Cited by 4
Engineering antibodies with cancer‐associated binding sites
Tian, Y., Pan, Y., Zhang, Y., Wang, F., & Wang, Z. (2024) · BMEMat · doi:10.1002/bmm2.12134 · Cited by 3
Nishi, T., Morita, A., Hara, N., Makimoto, G., Ninomiya, K., Fujii, M., Rai, K., Ohashi, K., Hotta, K., Tabata, M., et al. (2025) · Lung Cancer · doi:10.1016/j.lungcan.2025.108415 · Cited by 3
Paniagua‐Herranz, L., Doger, B., Díaz‐Tejeiro, C., Sanvicente, A., Nieto‐Jiménez, C., Moreno, V., Pérez‐Segura, P., Győrffy, B., Calvo, E., & Ocaña, A. (2023) · Cancers · doi:10.3390/cancers15123250 · Cited by 3
“In solid tumors, only one antibody, amivantamab, that targets EGFR and MET, has received regulatory approval for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations [14,15].”
BackgroundCuan, X., Yang, X., Wang, J., Sheng, J., Wang, X., & Huang, Y. (2024) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2024.107808 · Cited by 3
Amivantamab (JNJ-61186372)-induced adverse cutaneous reaction
Cheng, J., Hui, H., Zheng, J., Mao, H., Wang, Y., & Shi, B. (2023) · Indian Journal of Dermatology Venereology and Leprology · doi:10.25259/ijdvl_717_2022 · Cited by 3
The Implication of Liquid Biopsy in the Non-small Cell Lung Cancer: Potential and Expectation
Ren, J., & Liu, R. (2023) · Methods in molecular biology · doi:10.1007/978-1-0716-3346-5_10 · Cited by 3
Song, Y., Wang, Y., Guan, A., Xue, J., Li, B., Huang, Z., Zheng, Z., Liang, N., Yang, Y., & Li, S. (2023) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2023.1132940 · Cited by 5
Rosell, R., & Cardona, A. F. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.02.039 · Cited by 3
Fu, X., Zeng, D., Li, M., Wu, J., Yang, Y., Mao, Q., Qiu, W., Huang, X., Fang, Y., Jiang, L., et al. (2025) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2025.2471512 · Cited by 2
Furuya, N. (2025) · Future Oncology · doi:10.1080/14796694.2025.2550927 · Cited by 3
Sanborn, R. E., Zhou, C., Tang, K., Cho, B. C., Cheng, S. Y.-S., Popat, S., Ono, A., Lu, S., Majem, M., Aguilar, A., et al. (2025) · Targeted Oncology · doi:10.1007/s11523-025-01182-0 · Cited by 2
“Amivantamab is an EGFR-MET bispecific antibody with immune cell-directing activity [6–8] that has shown promising anti-tumor activity across multiple NSCLC settings, including patients with EGFR Ex20ins [9–13].”
Self-citationZhou, C., Tang, K.-J., Liu, B., Kim, S.-W., Kitazono, S., Ono, A., Thiagarajan, M., Hung, J., Boyer, M. J., Çil, T., et al. (2026) · Lung Cancer · doi:10.1016/j.lungcan.2026.109302 · Cited by 2
Self-citationZeng, Y., Li, Y., Du, Z., Shu, R., Fu, C., & Zeng, Q. (2026) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-026-05168-1 · Cited by 2
“Rybrevant as a fully human bispecific antibody targeting EGFR and MET, is the first FDA-approved bispecific antibody to treat NSCLC by engaging two distinct pathways (Moores et al. 2016; Yun et al. 2020; Brazel et al. 2022).”
Kawczak, P., & Bączek, T. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15083024 · Cited by 2
Wang, Z., Song, Y., Wang, A., & 刘宝山 (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1795614 · Cited by 5
“Amivantamab offers a novel therapeutic alternative for NSCLC patients resistant to third-generation EGFR-TKIs and MET amplification (Yun et al., 2020).”
New therapies in non-small cell lung cancer with EGFR exon 20 insertion mutations
Gil‐Sierra, M. D., Briceño-Casado, M. D. P., & Cristina, M.-R. (2023) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552231162545 · Cited by 3
“The scarcity of treatments for NSCLC with EGFR exon 20 insertion mutations represents a health challenge and an unmet need for healthcare.(21,29,30)”
BackgroundResearch and development of antibody-based novel anti-cancer drugs: An overview
Zhou, J., Deng, H. Y., & Xiao, H. (2023) · Intelligent Pharmacy · doi:10.1016/j.ipha.2023.05.004 · Cited by 3
TO MARKET, TO MARKET–2021: MACROMOLECULAR THERAPEUTICS
Agard, N. J., Dragovich, P. S., Kelly, R. L., Lim, S. A., Beal, A. M., Moench, I., Chen, S.-J., Gram, A. M., & Kung, P. (2022) · Medicinal chemistry reviews · doi:10.1021/mc-2022-vol57.ch25 · Cited by 2
Self-citationBeyond First-Line Epidermal Growth Factor Receptor (EGFR)-Tyrosine Kinase Inhibitors (TKI)
Warnecke, B., & Nagasaka, M. (2024) · Advances in Oncology · doi:10.1016/j.yao.2024.01.008 · Cited by 2
Zhang, M.-S., Yeh, Y., Huang, H., Lin, L.-W., Huang, Y.-L. O., Wang, L., Yao, L.-J., Hung, T.-C., Tseng, Y., Lee, Y., et al. (2024) · PLoS ONE · doi:10.1371/journal.pone.0301120 · Cited by 2
[Application and Research Progress of Lung Cancer Organoid in Precision Medicine for Lung Cancer].
Huang, Z., Li, B., Wang, Y., Xue, J., Wei, Z., Liang, N., & Li, S. (2024) · PubMed Central · doi:10.3779/j.issn.1009-3419.2024.106.07 · Cited by 4
Nakano, T., Okita, K., Okazaki, S., Yoshimoto, S., Masuko, S., Yagi, H., Kato, K., Tomioka, Y., Imai, K., Hamada, Y., et al. (2025) · FEBS Open Bio · doi:10.1002/2211-5463.13963 · Cited by 2
“These correlations are novel results for PDAC, whereas those of HER1-MET [61] and LAT1-ASCT2 [62] have been reported in various cancers and have contributed to a more detailed understanding of cancer biology and its application to cancer therapy.”
De, S. K. (2023) · Elsevier eBooks · doi:10.1016/b978-0-443-13312-1.00005-2 · Cited by 1
Lenz, G., Pereira, R. A., Tumelero, M., Peruzzo, N., Schwengber, W. K., Francisco, A. D. J. D. S., & Lago, L. S. (2025) · touchREVIEWS in Oncology & Haematology · doi:10.17925/ohr.2025.21.1.5 · Cited by 2
EGFR exon 20 insertion in non-small cell lung cancer
Panda, G. S., Noronha, V., Shetty, O. A., Yadav, S. C., Kumar, R., Patil, V., Chandrani, P., Janu, A., Mahajan, A., Chougule, A., et al. (2022) · Cancer Research Statistics and Treatment · doi:10.4103/crst.crst_77_22 · Cited by 2
The Value of Population Screening in Advancing Personalized Medicine in the Field of Lung Cancer
Mogenet, A., Greillier, L., & Tomasini, P. (2021) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s267437 · Cited by 2
“Moreover, specific EGFR exon 20 inhibitors such as TAK-788 (mobocertinib), or bispecific antibodies like amivantamab, showed promising results in this indication.(60,61) Taken together, all the above-mentioned targets do not exceed 20% of advanced NSCLC.”
BackgroundRefae, A. A., Shakra, R. I. A., & Ibrahim, E. M. (2024) · Oncology · doi:10.1159/000541415 · Cited by 1
Epidermal Growth Factor Receptor in COPD and Lung Cancer: Is Inflammation the Culprit?
Agraval, H., Sharma, J. R., & Yadav, U. C. S. (2025) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-3-031-93894-8_3 · Cited by 1
Regulation of receptor tyrosine kinase hetero-interactions
Smith, A. W., & Barrera, F. N. (2025) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2025.103187 · Cited by 1
Research insights and clinical opportunities of functional organoid-based platforms
Huang, Y., Shen, W., Li, K., Zhang, Y., Lv, Q., Wang, C., Mao, W., & Zhao, A. (2025) · Bio-Design and Manufacturing · doi:10.1631/bdm.2400519 · Cited by 1
“Listed clinical trials include those involving thyroid tumor‐ oids (NCT06482086), lung tumoroids (NCT03979170, NCT02535507 [115], and NCT02609776 [116]), esophageal tumoroids (NCT03416244 [118] and NCT04389177 [119]), gastric tumoroids (NCT06196554), breast tumoroids (NCT06102824), colorectal…”
Cui, P., Sun, G., Zhou, G., Guo, X., Huang, H., Yang, J., Li, N., Tan, J., Hu, Y., & Zhang, D. H. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2025.1758359 · Cited by 1
Wang, Z.-W., Zhang, X., Wang, Y.-X., Cai, M., Chen, J., Sang, M.-Y., Yang, H.-Y., Shi, L., Wei, J.-F., & Ding, Q. (2026) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-026-03686-7 · Cited by 2
“Amivantamab, an IgG1 bispecific antibody, can disrupt EGFR/MET’s ligands binding at the same time, partly overcomes the problem of poor single-targeted EGFR therapy [24].”
Immunological effects of amivantamab in EGFR or MET-expressing non-small cell lung cancer
Yoshichika, R., Mukohara, F., Yamada, K., Nagasaki, J., Watanabe, H., Ueda, Y., Suzawa, K., Shien, K., Toyooka, S., Ishino, T., et al. (2026) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-026-04369-0 · Cited by 3
“In addition, amivantamab has been reported to induce antitumor immune responses through antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP) activity, and trogo-cytosis by recruiting macrophages and natural killer cells via the Fc region [14, 15].”
InfluentialWu, J., Zhuo, J., Chen, Y.-C., Wang, S.-P., Hsieh, J.-F., & Shih, J. (2026) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2026.04.013 · Cited by 1
Soo, R. A., Fernández‐Peñas, P., Li, M., Voon, P. J., Tanizaki, J., Tseng, J., Tan, C. L., Dong, X. R., Prabhash, K., Kim, H. R., et al. (2026) · Lung Cancer · doi:10.1016/j.lungcan.2026.109405 · Cited by 1
Self-citationHarnessing multispecific antibodies for next-generation cancer treatments
Liu, W.-Q., Xiao-li, Z., & Fan, X. (2026) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2026.109073 · Cited by 1
Yang, C., Wang, Y., Sun, Y., Sun, Y., Zhang, R., Wang, C., Song, Y., Zhao, W. H., & Li, J. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1572115 · Cited by 2
Zhou, K., Li, X., Yang, Y., Hou, D., Wang, S., Lin, H., Yin, R., Ju, D., Zeng, X. L., & Wang, S. (2025) · Journal of Molecular Biology · doi:10.1016/j.jmb.2025.169399 · Cited by 3
Swaih, A. M., Talbot, S., Savoca, A., Thorpe, H., Flemington, V., Phillips, B. U., Colclough, N., McCoull, W., Radeva, V., Hargreaves, D., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102305 · Cited by 3
Unlocking the Immune System: Advances in Next-generation Immunotherapy for Lung Cancer
Choudhary, F., Safdar, A., Abdin, M. Z., & Farooqi, H. (2025) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/0113895575415429251007093531 · Cited by 1
Preventive strategies against brain metastases: current state of the art and future directions
Ippen, F. M., Konen, F. F., Hau, P., & Winkler, F. (2026) · Neurological Research and Practice · doi:10.1186/s42466-026-00467-7 · Cited by 1
“In patients with common (exon 19 deletion or L858R mutations) and uncommon (exon 20 insertions) EGFR mutations, amivantanab has furthermore shown promising results [ 38 , 39].”
Lau, L. Y., Sahib, N. R. B. M., Cangco, C. Y. P., & Tan, A. C. (2026) · Drugs · doi:10.1007/s40265-026-02329-7 · Cited by 1
Passiglia, F., Passaro, A., Gariazzo, E., Montrone, M., Pasello, G., Tiseo, M., Russano, M., Citarella, F., Muscarella, L. A., Pozzessere, D., et al. (2026) · Cancer · doi:10.1002/cncr.70476 · Cited by 1
“8 In the phase 1 CHRYSALIS trial, amivantamab monotherapy demonstrated a great antitumor activity along with a manageable safety profile in patients with advanced NSCLC harboring EGFRex20ins mutations who had progressed on or after platinum - based chemotherapy, showing an objective response rate…”
Jiao, G., Peng, H., Yang, Y., Liu, Y., Liu, X., Hu, Y., Dai, Y., Li, Z., & Zhao, Q. (2026) · Molecular Cancer · doi:10.1186/s12943-026-02685-8 · Cited by 1
“This feature suggests a practical direction for overcoming heterogeneity-driven therapeutic resistance [184, 185].”
Si, W., Zhou, J., & Jiang, M. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1864153 · Cited by 1
“…14 skipping mutations and EGFR exon 20 insertion mutations, LCOs have been employed to evaluate the anti-tumor activity of the multikinase inhibitor ensartinib and the bispeci fi c antibody amivantamab, with amivantamab demonstrating superior ef fi cacy compared with cetuximab or poziotinib (78, 79).”
[Advances in the Treatment of EGFR Exon 20ins Mutant NSCLC].
Xu, M., Luo, J., & Xu, R. (2023) · PubMed Central · doi:10.3779/j.issn.1009-3419.2023.101.05 · Cited by 2
Spira, A. I., Waters, D. D., Tao, R., Vadagam, P., He, J., Vanderpoel, J., Donnelly, A., & Lin, I. (2025) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2025.100944 · Cited by 2
Organising pneumonia following amivantamab treatment: a case report
Naulleau, G., Matton, L., Hutuca, I., Fremand, X., Jeny, F., & Duchemann, B. (2025) · Respiratory Medicine and Research · doi:10.1016/j.resmer.2025.101227 · Cited by 1
Cetuximab in Patients with Non-Small Cell Lung Cancer and EGFR Exon 20 Insertion Alterations.
Nikanjam, M., Kato, S., Adashek, J. J., & Kurzrock, R. (2022) · PubMed · Cited by 1
Zheng, Q., Chen, D., Wang, X., Yang, Y., Zhao, S., Dong, X., Ma, C., Zhang, X., Duan, H., Sun, Y., et al. (2022) · Annals of Translational Medicine · doi:10.21037/atm-22-2780 · Cited by 1
“However, the therapeutic efficacy of EGFR antibodies is only modest for tumors driven by mutant EGFR, whose activation largely relies on autophosphorylation rather than the binding of epithelial growth factor (39-41).”
BackgroundPancrazzi, A., Ognibene, A., Moncada, A., & Torre, V. (2021) · Global Medical Genetics · doi:10.1055/s-0041-1732481
Will CHRYSALIS turn into a butterfly?
Fuereder, T. (2022) · ESMO Open · doi:10.1016/j.esmoop.2022.100421
Progress of EGFR-TKI Combined with Bevacizumab in the Treatment of Lung Cancer
谢, 志. (2022) · Advances in Clinical Medicine · doi:10.12677/acm.2022.123258
Thérapies ciblées et carcinomes non à petites cellules : nouveautés
Stauber, R., Louis Gro, S., Nguyen‐Ngoc, T., Mederos, N., Bouchaab, H., Peters, S., & Abdelhamid, K. (2022) · JMIG · doi:10.53738/revmed.2022.18.782.970
EGFR-Directed Therapy in Lung Cancer
Kim, S. Y., Costa, D. B., Shibahara, D., Kobayashi, S. S., & Halmos, B. (2023) · Cambridge University Press eBooks · doi:10.1017/9781009342285
Self-citationEngineered bispecific antibodies as cancer therapy
Huang, S. (2023) · Utrecht University Repository (Utrecht University) · doi:10.33540/1737
Antibody-Based Biotherapeutics in Cancer
Barth, J. (2024) · Springer eBooks · doi:10.1007/978-3-031-30023-3_23
PHE1-based IgG-like antibody platform provides a novel strategy for enhanced T-cell immunotherapy
Wang, L., Jiang, H., Yin, X., Liang, T., Li, G., Ding, C., Yang, M., Zhang, L., Liu, J., & Xu, Y. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1415834
Mechahougui, H., Smekens, L., & Addeo, A. (2024) · healthbook TIMES Oncology Hematology · doi:10.36000/hbt.oh.2024.20.150 · Cited by 1
Masui, Y., Masuda, K., & Yoshida, T. (2025) · Haigan · doi:10.2482/haigan.65.71
Amivantamab Plus Chemotherapy in Japanese Patients With EGFR Exon 20 Insertions NSCLC
Kitazono, S., Ono, A., Kawamura, T., Hataji, O., Tanaka, H., Matsumoto, S., Watanabe, N., Nagashima, H., Oki, M., Takahashi, M., et al. (2025) · Cancer Science · doi:10.1111/cas.70180
“Amivantamab is a bispecific antibody that targets both the EGFR and cMET pathways as well as possessing immune cell-directing activity [7–9].”
Self-citationLiu, K., Jiang, T., Tan, Q.-Q., Chen, H., Zhou, Q. W., Zhang, X., Zheng, Z., Wu, Y.-L., Jia, J., & Yang, J. (2025) · Journal of International Medical Research · doi:10.1177/03000605251403824 · Cited by 1
Kim, S., Park, J. M., Park, S., Jung, E., Ko, D., Park, M., Seo, J., Nam, K. D., Kang, Y. K., Lee, K., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26635734
Self-citationWu, Q., Qian, W., Sun, X., & Jiang, S. (2022) · Figshare · doi:10.6084/m9.figshare.21301428
Kim, S., Park, J. M., Park, S., Jung, E., Ko, D., Park, M., Seo, J., Nam, K. D., Kang, Y. K., Lee, K., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26635737
Self-citationBispecifics: The future of therapeutic antibodies
Davis, J. H. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-29808-0.00093-5
Tang, R., Aizemaiti, A., Tamemoto, Y., Kume, R., Yasuda, K., Sato, K., Abo, H., Tsuji, K., Higashi, K., Kiyoshi, M., et al. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-013316
“These results suggest that anaphylaxis is not driven by general immunogenicity or immune checkpoint axis blockade, but rather by off-target Fc γ R engagement mediated by high affinity for Fc γ Rs.”
The future of targeted therapies for pediatric central nervous system tumors
Lindsay, H., & Bouffet, É. (2025) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdaf188
Millet, Y. A., Spira, A. I., Baik, C. S., Hong, M. H., Shum, E., Patel, J. D., Nguyen, D., Janne, P. A., Piotrowska, Z., Leighl, N. B., et al. (2026) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-25-1056
Self-citationRole of NOX2 in bone homeostasis and its application against bone diseases
Bao-Kai, T. I. A. N., Meng-Huan, L. I., Chang, B., & Xue-Jie, Y. I. (2026) · Shengming kexue · doi:10.3724/cbls.2026053
Koyfman, S. A., Bauman, J. E., Mohseni, M., Amit, M., Dadhania, D. M., Demehri, S., Divi, V., Geiger, J. L., Hanna, G. J., Kushalani, N., et al. (2026) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djag240
Advances in multi-scale computational approaches for kinase selectivity profiling
Qin, L., Tian, Y.-N., Gu, S., Zhai, S., Liu, H., & Yao, X. (2026) · Digital Discovery · doi:10.1039/d6dd00196c
Zhai, X., Rong, Z., Lixia, F., Gu, Y., Dong, B., Yao, D., Pang, X., & Cui, Y. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1884087
Eck, M. J., & Scott, D. A. (2026) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2024.0505 · Cited by 1
Jiang, L., Han, X., He, H., Peng, M., Yang, M., Pan, J., Liu, D., Feng, H., Yan, J., & Li, L. (2026) · hLife · doi:10.1016/j.hlife.2026.08.003
Advances in Bispecific Antibodies and Antibody–Drug Conjugates for Colorectal Cancer Treatment
Cappellino, M. G., Sullivan, S. P., High, P. C., Blackburn, T. A., & Carmon, K. S. (2026) · Antibodies · doi:10.3390/antib15050080
“For example, HER2 biparatopic antibodies and EGFR × c-MET bsAb amivantamab have been shown to induce receptor clustering and greater internalization than conventional mAbs, contributing to more effective receptor downregulation and signaling inhibition [20,32].”
Metadata
- Authors
- Yun, J., Lee, S.-H., Kim, S.-Y., Jeong, S.-Y., Kim, J.-H., Pyo, K.-H., Park, C.-W., Heo, S. G., Yun, M. R., Lim, S., Lim, S. M., Hong, M. H., Kim, H. R., Thayu, M., Curtin, J. C., Knoblauch, R. E., Lorenzi, M. V., Roshak, A., & Cho, B. C.
- Affiliations
- Yonsei University (KR)
- Jeuk (South Korea) (KR)
- 4Janssen Research and Development, Spring House, Pennsylvania.
- ORCID
- Venue
- Cancer Discovery
- Published
- 2020-08-01
- Volume
- 10
- Issue
- 8
- Pages
- 1194-1209
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- OpenAlex
- W3024670790
- Cited by
- 297
- References
- 47
- Citations by year
- 2026: 32 · 2025: 60 · 2024: 45 · 2023: 52 · 2022: 49 · 2021: 47 · 2020: 11
- FWCI
- 22.41
- Type
- journal article
- Language
- en
- Open access
- Licence
- cc-by-nc-nd
- Locations
- Cancer Discovery (publishedVersion)
- PubMed (publishedVersion)
- YUHSpace (Yonsei University Medical Library) (submittedVersion, cc-by-nc-nd)
- Funders
- Ministry of Science, ICT and Future Planning (NRF-2016R1A2B3016282, 2018R1C1B6008916)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- amivantamab, EGFR-MET bispecific antibody, EGFR exon 20 insertion, non-small cell lung cancer, anticancer activity, EGFR tyrosine kinase inhibitors, immune checkpoint blockade, interferon-gamma, patient-derived organoids, xenograft models, cetuximab, poziotinib, Ba/F3 cells
- MeSH terms
- Antineoplastic Agents, Immunological, Animals, Carcinoma, Non-Small-Cell Lung, Exons, Female, Humans, Lung Neoplasms, Mice, Inbred BALB C, Mice, Nude, Mutation, Antibodies, Bispecific, Proto-Oncogene Proteins c-met, Cell Line, Tumor, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.